Industry

Webcast to be held Monday Nov. 7, 4:30 p.m. ET, register here. DALLAS–(BUSINESS WIRE)–$LTRN—Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (A.I.) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will host its … [Read more…]

CARLSBAD, Calif.–(BUSINESS WIRE)–$LCTX #LineageCellTherapeutics—Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Jill Howe will join as the Company’s Chief Financial Officer, effective November 14, 2022. Ms. Howe brings more than 20 years of significant strategic, financial, and operational experience … [Read more…]

Expands Specialty Diagnostics Segment with Industry Leader in Oncology Testing for Detection and Monitoring of Multiple Myeloma Complements Existing Specialty Diagnostics Offering with Established Technologies Delivering Strong Clinical Value for Patients in a Rapidly Growing Diagnostics Segment WALTHAM, Mass.–(BUSINESS WIRE)–Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced … [Read more…]

LEXINGTON, Mass.–(BUSINESS WIRE)–$CNCE #AlopeciaAreata—Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the third quarter of 2022, on Monday, November 7, 2022, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss its third quarter 2022 financial results … [Read more…]

Study also shows DecisionDx-SCC is being appropriately utilized by clinicians treating patients with cutaneous squamous cell carcinoma and one or more risk factors, as evidenced by first-year clinical order data FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL #DecisionDxSCC–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of real-world … [Read more…]

Reblozyl, the first erythroid maturation agent, met primary and key secondary endpoints in the first-line treatment of patients with very low/low/intermediate-risk myelodysplastic syndromes PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #BMS—Bristol Myers Squibb (NYSE: BMY) today announced the COMMANDS study, a Phase 3, open-label, randomized trial evaluating Reblozyl® (luspatercept-aamt), met its primary endpoint, demonstrating a highly statistically significant and … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Infectious Respiratory Disease Diagnostics Market Share, Size, Trends, Industry Analysis Report, By Product, By Sample Type, By Application, By Technology, By End-Use, By Region, Segment Forecast, 2022 – 2030” report has been added to ResearchAndMarkets.com’s offering. The global infectious respiratory disease diagnostic market size is expected to reach USD 43.74 billion by 2030 … [Read more…]

− New activator in the GEMS (Gene Expression Modulation System) Platform addresses limitations of existing therapy modalities − − Persistent activation of genes may provide permanent cure for diseases such as haploinsufficient diseases − − Tunable protein expression mitigates the risk of toxic overexpression − SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Epic Bio, a biotechnology company developing … [Read more…]

Turnstone’s innovative approach with TIDAL-01 focuses on selecting and manufacturing the most potent tumor-reactive T-cells (Selected TILs) to overcome the limitations of current TIL-based therapies SAN DIEGO–(BUSINESS WIRE)–#SelectedTILs–Turnstone Biologics Corp, a clinical-stage biotechnology company developing next-generation immunotherapies to treat and cure solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared … [Read more…]

A short induction of Remodulin® (treprostinil) injection allowed study subjects to reach double the typical doses of Orenitram® (treprostinil) extended-release tablets than patients who did not have a Remodulin induction SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that a preliminary analysis of the … [Read more…]